Evelo Biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines _ monoclonal microbials. Evelo Therapeutics (Nasdaq:EVLO) is a microbiome company, developing Oncobiotic_ therapeutics, based on its deep understanding of cancer associated bacteria (CAB) and bacterial immune activators (BIA_) - microbiome based therapies for cancer.
Evelo BioSciences, Inc.
[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”EVLO” api=”yf” style=”font-size: 15px”]
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttps://evelobio.com
Disease Focus
STOCK CODENASDAQ: EVLO
Address620 Memorial Drive, Suite 200 West, MA, 02139CambridgeUnited States
620 Memorial Drive, Suite 200 West, MA, 02139
Cambridge
United States
Contact Number+1 617-870-1335
+1 617-870-1335
Evelo Therapeutics (Nasdaq:EVLO) is a microbiome company, developing Oncobiotic_ therapeutics, based on its deep understanding of cancer associated bacteria (CAB) and bacterial immune activators (BIA_) – microbiome based therapies for cancer.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/evelo-therapeutics” connections=”true” suffix=””]
Evelos Oncobiotic platform is designed to identify novel approaches leverage tumor-microenvironment modifications that can be mediated by the microbiome to disrupt tumor metabolism and the interactions between the tumor and surrounding tissue.
In Nov 2015, University of Chicago granted Evelo Therapeutics, an option to acquire exclusive, worldwide rights to develop its microbiome-based immunotherapy.
In May 2018, Evelo raised $85 Mn through Initial Public Offering. Earlier in Nov 2015, Flagship Ventures launched Evelo Therapeutics, with an initial capital commitment of $35 Mn USD to develop novel microbiome based therapies for cancer.